FY2025 EPS Estimates for TSHA Increased by Cantor Fitzgerald

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Cantor Fitzgerald lifted their FY2025 EPS estimates for Taysha Gene Therapies in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.36) for the year, up from their prior forecast of ($0.38). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same period in the prior year, the company posted ($0.10) EPS.

TSHA has been the topic of several other research reports. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.57.

Taysha Gene Therapies Price Performance

TSHA opened at $2.93 on Wednesday. The company has a 50-day moving average of $1.76 and a 200-day moving average of $1.84. The company has a market capitalization of $600.81 million, a P/E ratio of 4.65 and a beta of 0.90. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently made changes to their positions in TSHA. Ground Swell Capital LLC purchased a new position in Taysha Gene Therapies during the 4th quarter valued at about $25,000. Cibc World Markets Corp acquired a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $31,000. Hsbc Holdings PLC lifted its position in Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after buying an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $39,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.